SERA (30) BNR (20) XGN (36) TLSI (31) ⌘ Pro Terminal →

Kewaunee Scientific Corporation (KEQU) — RQD Stock Rating Cockpit

$33.51 -3.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $33.24

Kewaunee Scientific Corporation (KEQU) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $97.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KEQU Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.51 (-3.48% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #97 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KEQU compare to SERA and BNR in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, SERA (Sera Prognostics Inc. (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $81.3M) and BNR (Burning Rock Biotech Limited) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $116.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KEQU?

▼

Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $33.24 (-0.82%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 6.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KEQU)Realized 20D OHLCV Swing Band: ±5%

Deterministic 5-Pillar Attribution (69/100 Composite)

🔍 WHY KEQU SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 6.6% FCF Margin ($18.6M FCF) & 28.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$32.40-0.9% Next Q

Q2 (-2Q)

Grade C+$32.10+1% Next Q

Q3 (-1Q)

Grade B-$32.42+3.4% Next Q

Current

Grade C+$33.51+2% Hist 90D α

Trajectory: C (61) → C+ (69)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the KEQU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, KEQU faces multiple-compression risk if 10.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 26.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($34.54) or 200D SMA ($36.80) invalidates the momentum regime and cuts Target Base ($35.17) toward Bear Floor ($27.43).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KEQU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KEQU Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”

YES 69%NO 31%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.37>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE13% OF RANGE

L: $32$33.51H: $43

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (29% profit margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on KEQU

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (85)

16.7% ROIC with 28.5% gross margin and 19.20% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 3.37 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (60)

24/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like KEQU

✓Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (KEQU Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KEQU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.16%▼ DESCENDING CHANNEL

2026-11-02O $34.72H $34.72L $33.51C $33.51VOL 1.9K

RES: $37.31SUP: $31.13SMA50: $34.54SMA200: $36.80

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KEQU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KEQU Butterfly Map → + Track KEQU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-1.0%/yr Implied 5Y Growth

vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KEQU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KEQU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KEQU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KEQU)

Health Care Rank #97 of 1016 ⚔️ SERA vs KEQU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KEQU vs. SERA, BNR, XGN, TLSI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kewaunee Scientific Corporation (KEQU) ranks #97 by composite RQD confidence (69/100, grade C+) and #664 by equity capitalization ($97.0M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KEQU ACTIVE Kewaunee Scientific Corporation	C+	69/100	10.1x	28.5%	16.7%	-3.48%	$97.0M	Benchmark Subject
SERA Sera Prognostics Inc. (Class A)	E	30/100	—	-30.0%	-35.0%	+1.48%	$81.3M	/sera-vs-kequ →
BNR Burning Rock Biotech Limited	E	20/100	—	74.7%	-35.0%	-9.87%	$116.5M	/bnr-vs-kequ →
XGN Exagen Inc.	D-	36/100	—	58.3%	-35.0%	+3.57%	$210.8M	/xgn-vs-kequ →
TLSI TriSalus Life Sciences Inc.	E	31/100	—	84.6%	-35.0%	-1.78%	$237.7M	/tlsi-vs-kequ →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0000055529

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kewaunee Scientific Corporation (KEQU) reported GAAP revenue of $282.0M (+17.3% vs. FY2024 revenue of $240.5M , and +38.4% cumulative change since FY2023) , GAAP net income of $9.6M, operating cash flow of $18.6M, and free cash flow of $18.6M (+26.0% YoY). On the balance sheet, KEQU closed FY2025 with $176.0M in total assets against $16.3M in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$282.0M	$9.6M	$18.6M	$18.6M	$176.0M	$16.3M
FY2024 (FY)	2025-04-30	$240.5M	$11.4M	$14.8M	$14.8M	$189.1M	$35.0M
FY2023 (FY)	2024-04-30	$203.8M	$18.8M	$19.6M	$19.6M	—	—

3. KEQU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KEQU compare to SERA and BNR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KEQU?

Where is KEQU trading relative to its 50-day, 200-day, and 52-week technical levels?

KEQU last traded at $33.51 (-3.48% on volume of 1,890 shares), positioning the stock -2.98% below its 50-day simple moving average ($34.54) and -8.94% below its 200-day simple moving average ($36.80). Across its 52-week range of $32.00 to $43.36, KEQU sits at the 13.3% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±5.0% ($31.83 to $35.19).

KEQU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KEQU stock right now?

Kewaunee Scientific Corporation (KEQU) currently earns a Roarable Rating of C+ (Hold — HOLD) with 69/100 RQD Confidence. Solid 29% profit margin (17% return on capital), mixed timing at 10x P/E—hold if owned, no rush to chase.

What is KEQU's 12-month price target and RQD AI Jury consensus?

KEQU's 12-month base price target is $35.17 (range $27.43 to $45.53), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KEQU RQD Cockpit KEQU 12M Forecast KEQU Earnings & Move KEQU Dividends & DRIP KEQU Insiders & 13F KEQU Whale Options KEQU Profit Sankey KEQU News & Why